Panacea finds no cure-all for its financial woes
This article was originally published in Scrip
Panacea Biotec, India's second largest vaccine producer, finds itself in an unenviable financial position with substantial net worth erosion, highlighting what some experts say are the perils of dependence on "binary" tender-based bulk purchases.
You may also be interested in...
Bharat Biotech's quadrivalent (DPT-Hib) vaccine will have to go through Phase III trials after rival Panacea Biotec questions India's market authorization of the product.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?